GRI Bio Inc
Research GRI Bio Inc (GRI) on Bullrun: market cap USD 3.47M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGRI
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 3.47M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 2.00M
- Free cash flow-USD 3.69M
Valuation Snapshot
latest market cap is USD 3.47M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 11.96M | -USD 10.19M | n/a | -121.8 | USD 8.23M | USD 71.00K | USD 6.01M |
| FY2024 | USD 0 | -USD 8.21M | -USD 8.61M | n/a | -1545.55 | USD 5.03M | USD 119.00K | USD 4.03M |
| FY2023 | n/a | -USD 13.04M | -USD 9.00M | n/a | -5018.09 | USD 1.81M | USD 14.00K | USD 259.00K |
| FY2022 | n/a | -USD 3.22M | -USD 1.09M | n/a | -24.95 | USD 9.00K | n/a | -USD 1.63M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 3.47M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 3.44M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 7.41M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.67M | n/a | n/a | n/a |
About GRI Bio Inc
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is GRI Bio Inc's market cap?
GRI Bio Inc's market capitalization is USD 3.47M.
What does GRI Bio Inc do?
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.